Gilead Sciences
GILD
1,597 hedge funds and large institutions have $86.8B invested in Gilead Sciences in 2016 Q2 according to their latest regulatory filings, with 94 funds opening new positions, 653 increasing their positions, 719 reducing their positions, and 112 closing their positions.
9% less repeat investments, than reductions
Existing positions increased: 653 | Existing positions reduced: 719
2% less funds holding
Funds holding: 1,630 → 1,597 (-33)
11% less capital invested
Capital invested by funds: $97.1B → $86.8B (-$10.3B)
16% less first-time investments, than exits
New positions opened: 94 | Existing positions closed: 112
30% less call options, than puts
Call options by funds: $1.38B | Put options by funds: $1.99B
31% less funds holding in top 10
Funds holding in top 10: 187 → 129 (-58)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$300M |
| 2 |
Parnassus Investments
San Francisco,
California
|
+$234M |
| 3 |
Goldman Sachs
New York
|
+$199M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$172M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$159M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal London Asset Management
United Kingdom
|
-$2.7B |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$917M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
-$506M |
| 4 |
ECU
Egerton Capital (UK)
London,
United Kingdom
|
-$277M |
| 5 |
Barclays
London,
United Kingdom
|
-$247M |
GILD Hedge Fund Activity: Q2 2016 in Review
1,597 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q2 2016, worth a combined $86.8B — down 11% from $97.1B a quarter earlier.
Sellers outnumbered buyers: 112 funds closed out of GILD and 94 opened new positions — a net loss of 18 holders — while 719 trimmed existing stakes and 653 added.
The largest buyer was Capital World Investors, adding an estimated $300M. The largest seller was Royal London Asset Management, cutting an estimated $2.7B.
- 1,597 institutional investors held Gilead Sciences (GILD) as of Q2 2016, down from 1,630 in Q1 2016.
- Funds reported $86.8B of Gilead Sciences stock for Q2 2016, down 11% quarter-over-quarter.
- 94 funds opened new Gilead Sciences positions in Q2 2016 and 112 closed out, a net change of -18 holders.
- The largest Gilead Sciences buyer in Q2 2016 was Capital World Investors, an estimated $300M added.
- The largest Gilead Sciences seller in Q2 2016 was Royal London Asset Management, an estimated $2.7B sold.
Based on aggregated 13F filings for Q2 2016.